Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia

2000 ◽  
Vol 101 (4) ◽  
pp. 279-282 ◽  
Author(s):  
J. Kalman ◽  
J. Marki-Zay ◽  
A. Juhasz ◽  
A. Santha ◽  
L. Dux ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cystatin C ◽  
Alzheimer’S Dementia ◽  
Alzheimer's Dementia

scholarly journals P4-180: BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER'S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE

2019 ◽  
Vol 15 ◽  
pp. P1344-P1345
Author(s):  
Fabricio Ferreira de Oliveira ◽  
Marjorie Câmara Miraldo ◽  
Eduardo Ferreira Castro-Neto ◽  
Fernando Chiodini Machado ◽  
Sandro Soares de Almeida ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Alzheimer’S Dementia ◽  
Healthy People ◽  
Carrier Status ◽  
Behavioral Correlates ◽  
Alzheimer's Dementia ◽  
Apoe Ε4 ◽  
Cerebrospinal Fluid Biomarkers

Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid

2002 ◽  
Vol 23 (4) ◽  
pp. 485-508 ◽  
Author(s):  
C.E. Teunissen ◽  
J. de Vente ◽  
H.W.M. Steinbusch ◽  
C. De Bruijn
Keyword(s):  
Cerebrospinal Fluid ◽  
Biochemical Markers ◽  
Alzheimer’S Dementia ◽  
Alzheimer's Dementia

scholarly journals A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment

2017 ◽  
Vol 9 (1) ◽  
Author(s):  
Marco Vinceti ◽  
Annalisa Chiari ◽  
Marcel Eichmüller ◽  
Kenneth J. Rothman ◽  
Tommaso Filippini ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Alzheimer’S Dementia ◽  
Alzheimer's Dementia ◽  
Selenium Species

scholarly journals Cerebrospinal fluid AΒ 42 , total tau, and phosphorylated tau in the evaluation of Alzheimer’s dementia: Experience from a commercial reference laboratory

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Sat Dev Batish ◽  
Farnoosh Haji‐Sheikhi ◽  
Amogh Kare ◽  
Vivekananda Datta ◽  
Marc Meservey ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Alzheimer’S Dementia ◽  
Reference Laboratory ◽  
Phosphorylated Tau ◽  
Alzheimer's Dementia ◽  
Total Tau

Lead (Pb) in Alzheimer’s Dementia: A Systematic Review of Human Case- Control Studies

2019 ◽  
Vol 16 (4) ◽  
pp. 353-361 ◽  
Author(s):  
Eric E. Brown ◽  
Parita Shah ◽  
Bruce G. Pollock ◽  
Philip Gerretsen ◽  
Ariel Graff-Guerrero
Keyword(s):  
Cerebrospinal Fluid ◽  
Human Case ◽  
Case Control ◽  
Alzheimer’S Dementia ◽  
Future Research ◽  
Case Control Studies ◽  
Alzheimer's Dementia ◽  
Pb Exposure ◽  
Meta Analyses

Background: Alzheimer’s Dementia (AD) has a complex pathophysiology that is incompletely understood. Chronic, low-level environmental lead (Pb) exposure is associated with cognitive impairment, hypertension and mortality, and has been proposed as a potential cause of AD. Objective: We aimed to review the literature to clarify the potential role of Pb in AD and to guide future research. Methods: Through a series of systematic reviews, we identified case-control studies comparing AD to controls on 6 measures of Pb exposure or accumulation: blood, bone, cerebrospinal fluid, hair/nail, postmortem pathology, and urine. We completed meta-analyses where possible. Results: The number of identified case-control studies of AD, by measurement method, was: 15 by blood, 0 by bone, 5 by Cerebrospinal Fluid (CSF), 3 by hair/nail, 3 by postmortem, and 1 by urine. Two meta-analyses were possible for 7 studies reporting whole blood Pb and for 8 studies of serum Pb. Both were negative. The largest study of CSF Pb showed lower levels in AD. Similarly, lower hair Pb levels were found in AD. Conclusion: The available case-control studies are insufficient to draw conclusions on the role of Pb in AD. Most methods do not address long-term or early-life exposure. The preferred measure of chronic Pb is in bone, which has not been utilized in case-control AD studies. Future research should measure bone Pb in AD, together with other biomarkers, such as amyloid and tau imaging, and markers of cerebrovascular pathology.

The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimer'sDisease from Non-Alzheimer's Dementia

2010 ◽  
Vol 999 (999) ◽  
pp. 1-10
Author(s):  
P.E. Spies ◽  
D. Slats ◽  
J.M.C. Sjogren ◽  
B.P.H. Kremer ◽  
F.R.J. Verhey ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Alzheimer’S Dementia ◽  
Alzheimer's Dementia
Sign in / Sign up

Export Citation Format

Share Document